🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Acumen Pharmaceuticals, Inc. ABOS PHARMA

Healthcare · Biotechnology · United States
https://acumenpharm.com
Company Profile ↓
$3.16
+148.82% 1Y
Mkt Cap$228.52M
P/E-1.93
P/B3.60
52W High$3.37
52W Low$1.23
Book Value$0.79
EPS (TTM)$-1.64

Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Recent Developments

  • 5-Year Trend Long-term compounding — profit CAGR -61.0%.

Growth & Price Performance

Compounded Profit Growth

5 Years:-61.04%
1 Year:-

Stock Price Performance

1 Year:+148.82%
6 Months:+0.64%
3 Months:+45.62%
1 Month:+29.51%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 90% of range
$1.23 $3.37
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)66.30 · Neutral
Price Performance
1M+29.51%
3M+45.62%
6M+0.64%
1Y+148.82%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -61.0% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.93
Industry PE
24.83
Forward P/E
-2.21
PEG Ratio
-
Book Value
$0.79
Price to Book
3.60
P/S
-
EV/EBITDA
-1.42
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-61.04%
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-126.16%
ROE
-120.50%
ROA
-45.77%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.33
EPS (TTM)
$-1.64

Balance Sheet & Liquidity

Debt/Equity
0.55
Quick Ratio
2.38
Current Ratio
2.47
Debt
$31.65M
Total Assets
$133.63M
Current Assets
$133.09M
Working Capital
$92.25M

Ownership

Promoter Holding
6.79%
Chg in Prom Hold
-0.01%
FII / Inst Holding
66.60%
Chg in FII Hold
0.02%

Financial Snapshot

Enterprise Value
$228.52M
Total Revenue (TTM)
$0
EBITDA
$-105.37M
Free Cash Flow
$-56.50M
Operating Cash Flow
$-91.79M
Shares Outstanding
72.32M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABOS Acumen Pharmaceuticals, Inc. PHARMA 3.16 -1.93 $228.52M 0.00% -126.16% -120.50% - -61.04%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --------------00000
Cost of Revenue -------------------
Gross Profit -------------------
Operating Expenses --------------30.37M41.75M26.51M25.20M21.15M
Operating Income -2.04M-2.49M-3.79M-3.44M-3.94M-9.21M-10.41M-11.37M-13.13M-13.48M-16.04M-17.77M-24.38M-32.27M-30.37M-41.75M-26.51M-25.20M-21.15M
EBITDA ---------------27.73M-39.86M-25.34M-24.01M-19.62M
Interest Expense --------------1.02M1.05M1.07M1.09M1.07M
Pretax Income ---------------28.80M-40.95M-26.45M-25.14M-20.74M
Tax Provision -------------------
Net Income -2.04M-2.49M-27.00M-61.36M-3.90M-9.13M-10.15M-10.71M-11.31M-11.61M-12.96M-14.87M-20.54M-29.77M-28.80M-40.95M-26.45M-25.14M-20.74M
Diluted EPS ----141.93-0.10-0.23-0.25-0.26-0.28-0.28-0.24-0.25-0.34-0.50-0.48-0.68-0.44--0.33
R&D Expense 1.93M2.99M2.58M2.25M1.80M5.99M7.32M8.31M8.71M9.13M11.18M12.45M19.53M27.25M25.27M37.12M21.97M-16.48M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --0000
Cost of Revenue ------
Gross Profit ------
Operating Expenses --45.24M61.14M114.02M123.83M
Operating Income -7.91M--45.24M-61.14M-114.02M-123.83M
EBITDA ---42.69M-51.61M-98.08M-116.93M
Interest Expense --0581.00K4.07M4.22M
Pretax Income ---42.86M-52.37M-102.33M-121.33M
Tax Provision ------
Net Income -7.33M--42.86M-52.37M-102.33M-121.33M
Diluted EPS ---1.06-1.08-1.71-2.00
R&D Expense 8.00M12.30M32.36M42.32M93.80M104.89M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -44.43M-196.59M310.12M238.99M122.83M
Current Assets ---180.33M246.62M178.31M122.25M
Cash & Equivalents 6.55M43.78M-130.10M66.89M35.63M53.99M
Inventory -------
Receivables ---0225.00K345.00K625.00K
Total Liabilities -6.37M-7.81M43.15M57.18M52.40M
Current Liabilities ---7.81M12.97M27.61M30.01M
Long Term Debt ----27.34M28.45M22.40M
Total Debt ---105.00K28.49M28.73M31.31M
Total Equity -11.42M-18.59M-188.78M266.97M181.82M70.43M
Shares Outstanding ---41.03M57.91M60.09M60.58M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -7.45M--35.15M-43.06M-86.22M-115.54M
Investing Cash Flow --39.19M-171.67M48.03M133.93M
Financing Cash Flow 44.67M-3.91M151.75M6.93M-34.00K
Capital Expenditure ---161.00K-21.00K-16.00K-88.00K
Free Cash Flow ---35.31M-43.09M-86.23M-115.63M
Net Change in Cash --7.94M-62.98M-31.26M18.36M

Ratios (Annual)

Figures in %.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------
Operating Margin % ------
Net Margin % ------
ROE % 39.4%--22.7%-19.6%-56.3%-172.3%
ROCE % ---24.0%-20.6%-53.9%-133.4%

Shareholding Pattern

Insiders
6.79%
Institutions
66.60%
Public Float
71.46%

Top Institutional Holders

#Holder% HeldSharesValue
1 RA Capital Management, L.P. 29.03% 20.99M $55.63M
2 Sands Capital Alternatives, LLC 5.14% 3.72M $9.86M
3 Blackrock Inc. 3.44% 2.49M $6.60M
4 Alyeska Investment Group, L.p. 3.39% 2.45M $6.51M
5 Franklin Resources, Inc. 3.19% 2.31M $6.11M
6 Adar1 Capital Management, LLC 2.92% 2.11M $5.60M
7 Vanguard Capital Management LLC 2.31% 1.67M $4.43M
8 Knollwood Investment Advisory, LLC 2.25% 1.63M $4.32M
9 Geode Capital Management, LLC 1.58% 1.14M $3.03M
10 Ikarian Capital, LLC 1.46% 1.05M $2.79M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABOS

Yahoo Finance Wed, 12 Aug 2026

Acumen Pharmaceuticals Inc (ABOS) (Q2 2026) Earnings Call Highlights: Advancing Sabirnetug ...

Acumen Pharmaceuticals Inc (ABOS) reports strong progress on its lead Alzheimer's candidate and next-generation pipeline, with cash runway into early 2027.

Yahoo Finance Wed, 12 Aug 2026

Acumen Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Moby summary of Acumen Pharmaceuticals, Inc.'s Q2 2026 earnings call

Yahoo Finance Wed, 05 Aug 2026

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligom…

Yahoo Finance Wed, 15 Jul 2026

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo Finance Wed, 15 Jul 2026

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

Yahoo Finance Wed, 15 Jul 2026

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device and reduce the delivered dose required f…

ABOS — Frequently Asked Questions

What is the current share price of Acumen Pharmaceuticals, Inc. (ABOS)?

As of 2026-09-19 21:16 PDT, Acumen Pharmaceuticals, Inc. (ABOS) trades at $3.16 on NasdaqGS. Its 52-week range is $1.23 to $3.37.

What is the market capitalisation of ABOS?

Acumen Pharmaceuticals, Inc. (ABOS) has a market capitalisation of $228.52M on NasdaqGS.

What is the P/E ratio of ABOS?

ABOS trades at a trailing price-to-earnings (P/E) ratio of -1.93. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.60.

What is the return on equity (ROE) of ABOS?

ABOS has a return on equity (ROE) of -120.50%. Its return on capital employed (ROCE) is -126.16%.

Is ABOS a good stock to buy?

This page provides a data-driven analysis of Acumen Pharmaceuticals, Inc. (ABOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space